• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌中的基因改变:最新进展

Genetic alterations in hepatocellular carcinoma: An update.

作者信息

Niu Zhao-Shan, Niu Xiao-Jun, Wang Wen-Hong

机构信息

Zhao-Shan Niu, Laboratory of Micromorphology, School of Basic Medicine, Medical Department of Qingdao University, Qingdao 266071, Shandong Province, China.

出版信息

World J Gastroenterol. 2016 Nov 7;22(41):9069-9095. doi: 10.3748/wjg.v22.i41.9069.

DOI:10.3748/wjg.v22.i41.9069
PMID:27895396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5107590/
Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Although recent advances in therapeutic approaches for treating HCC have improved the prognoses of patients with HCC, this cancer is still associated with a poor survival rate mainly due to late diagnosis. Therefore, a diagnosis must be made sufficiently early to perform curative and effective treatments. There is a need for a deeper understanding of the molecular mechanisms underlying the initiation and progression of HCC because these mechanisms are critical for making early diagnoses and developing novel therapeutic strategies. Over the past decade, much progress has been made in elucidating the molecular mechanisms underlying hepatocarcinogenesis. In particular, recent advances in next-generation sequencing technologies have revealed numerous genetic alterations, including recurrently mutated genes and dysregulated signaling pathways in HCC. A better understanding of the genetic alterations in HCC could contribute to identifying potential driver mutations and discovering novel therapeutic targets in the future. In this article, we summarize the current advances in research on the genetic alterations, including genomic instability, single-nucleotide polymorphisms, somatic mutations and deregulated signaling pathways, implicated in the initiation and progression of HCC. We also attempt to elucidate some of the genetic mechanisms that contribute to making early diagnoses of and developing molecularly targeted therapies for HCC.

摘要

肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。尽管近年来肝癌治疗方法的进展改善了肝癌患者的预后,但这种癌症的生存率仍然很低,主要原因是诊断较晚。因此,必须尽早做出诊断,以便进行根治性和有效的治疗。有必要更深入地了解HCC发生和发展的分子机制,因为这些机制对于早期诊断和开发新的治疗策略至关重要。在过去十年中,在阐明肝癌发生的分子机制方面取得了很大进展。特别是,新一代测序技术的最新进展揭示了许多基因改变,包括HCC中反复突变的基因和失调的信号通路。更好地了解HCC中的基因改变可能有助于未来识别潜在的驱动突变并发现新的治疗靶点。在本文中,我们总结了目前关于基因改变的研究进展,包括基因组不稳定性、单核苷酸多态性、体细胞突变和失调的信号通路,这些改变与HCC的发生和发展有关。我们还试图阐明一些有助于早期诊断HCC和开发分子靶向治疗的遗传机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/5107590/1e723af0be1e/WJG-22-9069-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/5107590/1e723af0be1e/WJG-22-9069-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c25/5107590/1e723af0be1e/WJG-22-9069-g001.jpg

相似文献

1
Genetic alterations in hepatocellular carcinoma: An update.肝细胞癌中的基因改变:最新进展
World J Gastroenterol. 2016 Nov 7;22(41):9069-9095. doi: 10.3748/wjg.v22.i41.9069.
2
The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action.Hippo 通路在肝细胞癌中的作用:非编码 RNA 的作用。
Cancer Lett. 2017 Aug 1;400:175-182. doi: 10.1016/j.canlet.2017.04.032. Epub 2017 Apr 29.
3
Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌中异常Wnt信号通路的综合分析
World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317.
4
CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.成年小鼠肝脏的CRISPR/Cas9基因编辑表明,Dnajb1-Prkaca基因融合足以诱发类似纤维板层型肝细胞癌的肿瘤。
Gastroenterology. 2017 Dec;153(6):1662-1673.e10. doi: 10.1053/j.gastro.2017.09.008. Epub 2017 Sep 18.
5
Genetics of hepatobiliary carcinogenesis.肝胆癌发生的遗传学。
Semin Liver Dis. 2011 May;31(2):173-87. doi: 10.1055/s-0031-1276646. Epub 2011 May 2.
6
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.肝癌细胞系分析鉴定出可能对肝细胞癌有效和有反应标志物的药物。
Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.
7
Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.表观遗传异常在人类肝细胞癌发生发展中的作用。
Cancer Lett. 2014 Jan 28;342(2):223-30. doi: 10.1016/j.canlet.2012.01.038. Epub 2012 Feb 2.
8
Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.下一代测序揭示了肝细胞癌的遗传图谱。
Cancer Lett. 2013 Nov 1;340(2):247-53. doi: 10.1016/j.canlet.2012.09.027. Epub 2012 Oct 12.
9
Pathways and gene expression profiles in hepatocellular carcinoma.肝细胞癌中的信号通路与基因表达谱
Minerva Gastroenterol Dietol. 2012 Mar;58(1):35-48.
10
Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.生物标志物在人类肝细胞癌发病机制和治疗中的意义。
World J Gastroenterol. 2014 Aug 14;20(30):10249-61. doi: 10.3748/wjg.v20.i30.10249.

引用本文的文献

1
Evaluation of the Variability in Selenoprotein Genes in Hepatocellular Carcinoma Patients.肝细胞癌患者硒蛋白基因变异性的评估
Biochem Genet. 2025 Aug 12. doi: 10.1007/s10528-025-11220-1.
2
Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions.不可切除肝细胞癌的系统治疗:现状与未来方向
Int J Mol Sci. 2025 Jun 22;26(13):5994. doi: 10.3390/ijms26135994.
3
Network-based analysis of candidate oncogenes and pathways in hepatocellular carcinoma.基于网络的肝细胞癌候选致癌基因和信号通路分析

本文引用的文献

1
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?肝细胞癌:新型靶向药物真的会影响未来吗?
World J Gastroenterol. 2016 Jul 21;22(27):6114-26. doi: 10.3748/wjg.v22.i27.6114.
2
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges.肝细胞癌中的肿瘤异质性:面对挑战
Liver Cancer. 2016 Apr;5(2):128-38. doi: 10.1159/000367754. Epub 2016 Mar 17.
3
Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology.肝细胞癌:探究种族对分子生物学的影响。
Biochem Biophys Rep. 2025 Jun 10;43:102086. doi: 10.1016/j.bbrep.2025.102086. eCollection 2025 Sep.
4
DNA methylation-driven genes in hepatocellular carcinoma patients: insights into immune infiltration and prognostic implications.肝细胞癌患者中DNA甲基化驱动的基因:对免疫浸润及预后意义的见解
Front Med (Lausanne). 2025 Apr 28;12:1520380. doi: 10.3389/fmed.2025.1520380. eCollection 2025.
5
Astrocyte Elevated Gene-1/Metadherin (AEG-1/MTDH): A Promising Molecular Marker and Therapeutic Target for Hepatocellular Carcinoma.星形胶质细胞上调基因1/黏附素(AEG-1/MTDH):一种有前景的肝细胞癌分子标志物和治疗靶点。
Cancers (Basel). 2025 Apr 21;17(8):1375. doi: 10.3390/cancers17081375.
6
Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000 to 2019.2000年至2019年期间,美国早发性和晚发性成人肝癌发病率的时间趋势和模式因种族/族裔、亚部位和组织学类型而异。
Cancer Causes Control. 2025 May;36(5):551-560. doi: 10.1007/s10552-024-01955-4. Epub 2025 Jan 9.
7
Gene targets with therapeutic potential in hepatocellular carcinoma.肝细胞癌中具有治疗潜力的基因靶点。
World J Gastrointest Oncol. 2024 Dec 15;16(12):4543-4547. doi: 10.4251/wjgo.v16.i12.4543.
8
Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma.基因改变与肝细胞癌的临床病理特征及复发/转移风险相关。
Eur J Cancer Prev. 2025 Sep 1;34(5):456-466. doi: 10.1097/CEJ.0000000000000939. Epub 2024 Nov 27.
9
Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis.超低通量全基因组测序检测不同癌症类型中循环肿瘤DNA的预后价值:一项系统综述和患者水平生存数据的荟萃分析。
Carcinogenesis. 2025 Jan 20;46(1). doi: 10.1093/carcin/bgae073.
10
An overview of risk assessment and monitoring of malignant transformation in cirrhotic nodules.肝硬化结节恶性转化的风险评估与监测概述
Therap Adv Gastroenterol. 2024 Oct 27;17:17562848241293019. doi: 10.1177/17562848241293019. eCollection 2024.
Crit Rev Oncol Hematol. 2016 Sep;105:65-72. doi: 10.1016/j.critrevonc.2016.06.007. Epub 2016 Jun 16.
4
[Prostate cancer and oxidative stress].[前列腺癌与氧化应激]
Nihon Rinsho. 2016 May 20;74 Suppl 3:71-4.
5
Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.染色质重塑基因富含AT交互结构域蛋白1A通过靶向磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α(PIK3CA)和丙酮酸脱氢酶激酶1(PDK1)抑制胃癌细胞增殖。
Oncotarget. 2016 Jul 19;7(29):46127-46141. doi: 10.18632/oncotarget.10060.
6
Interplay between Reactive oxygen Species and MicroRNAs in Cancer.癌症中活性氧与微小RNA之间的相互作用
Curr Pharmacol Rep. 2016 Apr;2(2):82-90. doi: 10.1007/s40495-016-0051-4. Epub 2016 Feb 9.
7
Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.乙型肝炎和丙型肝炎相关肝细胞癌中TERT启动子和CTNNB1基因的肿瘤特异性突变
Oncotarget. 2016 Aug 23;7(34):54253-54262. doi: 10.18632/oncotarget.9801.
8
The Dual Roles of NRF2 in Cancer.NRF2 在癌症中的双重作用。
Trends Mol Med. 2016 Jul;22(7):578-593. doi: 10.1016/j.molmed.2016.05.002. Epub 2016 Jun 2.
9
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.通过靶向深度测序对肝细胞癌患者循环游离DNA中的肿瘤相关突变进行无创检测。
Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629.
10
Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma.磷酸化p62的积累与肝细胞癌中NF-E2相关因子2的激活有关。
J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):467-71. doi: 10.1002/jhbp.364. Epub 2016 Jul 15.